Dolphin
Senior Member (Voting Rights)
https://www.frontiersin.org/articles/10.3389/fnins.2023.1286340/abstract
A cross-sectional study exploring the relationship between symptoms of anxiety/depression and P50 sensory gating in adult patients diagnosed with chronic fatigue syndrome/myalgic encephalomyelitis
Zhandong Liu1* 
Xinyi Liu1 Runtao Ren1 
Xue Wang1 Chunyu Han1
The final, formatted version of the article will be published soon.
Chronic fatigue syndrome (CFS) is a clinical disease that affects multiple body systems.
It is characterized by persistent or recurring fatigue, which may be linked to immune, neuroendocrine, and energy metabolism dysfunctions.
Individuals with CFS may experience pain, sleep disorders, anxiety, and depression. This research analyzed the fundamental characteristics of anxiety/depression symptoms in patients with CFS and investigated the association between these symptoms and the P50 SG (sensory gate) ratio.
249 subjects fulfilled the CDC-1994 criteria for CFS and were included in the study.
The subjects successively completed the Symptom CheckList-90-Revised (SCL-90-R), Hamilton Anxiety Rating Scale-14 (HAMA-14), and Hamilton Depression Rating Scale-24 (HAMD-24).
Auditory-evoked potential P50 were measured using the 128-lead-electroencephalograph.
According to HAMA and HAMD, 17.3% (n=43) of the patients did not exhibit anxiety/depression, with a threshold score of 7 and 7 for HAMA and HAMD.
When the threshold score was 14 and 20 respectively, 43.3% (n=108) of the patients did not exhibit anxiety/depression.
The SCL-90-R results indicated that 69.5% (n=173) of these individuals with the score arranging from 0 to 160 did not present mental problems.
There was a correlation between somatization scores and P50 SG ratio in the overall sample and NAOD (No anxiety or depression) group delimited by 14 and 20 respectively (p<0.05).
Regression analysis showed that anxiety and depression were risk factors associated with an abnormal P50 SG ratio.
A significant correlation exists between the P50 SG ratio and clinical symptoms such as fatigue, anxiety, and depression.
Abnormalities in brain function among patients with CFS may play a crucial role in the pathogenesis of the condition, leading to their classification as being prone to functional neurological disorders.
The P50 SG ratio cannot be used as a diagnostic marker for CFS but show some significance on the mechanism, classification, treatment, and prognosis of CFS.
A cross-sectional study exploring the relationship between symptoms of anxiety/depression and P50 sensory gating in adult patients diagnosed with chronic fatigue syndrome/myalgic encephalomyelitis
Zhandong Liu1* Xinyi Liu1 Runtao Ren1 Xue Wang1 Chunyu Han1- 1Affiliated Beijing Friendship Hospital, Capital Medical University, China
The final, formatted version of the article will be published soon.
Chronic fatigue syndrome (CFS) is a clinical disease that affects multiple body systems.
It is characterized by persistent or recurring fatigue, which may be linked to immune, neuroendocrine, and energy metabolism dysfunctions.
Individuals with CFS may experience pain, sleep disorders, anxiety, and depression. This research analyzed the fundamental characteristics of anxiety/depression symptoms in patients with CFS and investigated the association between these symptoms and the P50 SG (sensory gate) ratio.
249 subjects fulfilled the CDC-1994 criteria for CFS and were included in the study.
The subjects successively completed the Symptom CheckList-90-Revised (SCL-90-R), Hamilton Anxiety Rating Scale-14 (HAMA-14), and Hamilton Depression Rating Scale-24 (HAMD-24).
Auditory-evoked potential P50 were measured using the 128-lead-electroencephalograph.
According to HAMA and HAMD, 17.3% (n=43) of the patients did not exhibit anxiety/depression, with a threshold score of 7 and 7 for HAMA and HAMD.
When the threshold score was 14 and 20 respectively, 43.3% (n=108) of the patients did not exhibit anxiety/depression.
The SCL-90-R results indicated that 69.5% (n=173) of these individuals with the score arranging from 0 to 160 did not present mental problems.
There was a correlation between somatization scores and P50 SG ratio in the overall sample and NAOD (No anxiety or depression) group delimited by 14 and 20 respectively (p<0.05).
Regression analysis showed that anxiety and depression were risk factors associated with an abnormal P50 SG ratio.
A significant correlation exists between the P50 SG ratio and clinical symptoms such as fatigue, anxiety, and depression.
Abnormalities in brain function among patients with CFS may play a crucial role in the pathogenesis of the condition, leading to their classification as being prone to functional neurological disorders.
The P50 SG ratio cannot be used as a diagnostic marker for CFS but show some significance on the mechanism, classification, treatment, and prognosis of CFS.
